Aurobindo Pharma Ltd

10 patents currently held · Updated Nov 14, 2026

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 5 name spellings.

Ending by 2030

Mar 2035

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Jul 2, 2027
The maintenance fee for Pharmaceutical composition comprising Canagliflozin, process of preparation and use thereof (US 11,857,559) comes due Jul 2, 2027. Unpaid by Jan 3, 2028, it lapses early.
2 fees due Oct 28 to 30, 2027 · next Oct 28
1 fee due Nov 7, 2027
The maintenance fee for Naloxegol oxalate and solid dispersion thereof (US 11,974,996) comes due Nov 7, 2027. Unpaid by May 8, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 10 of 10

Patent	Title	Status	Expires	Confidence
US 11,096,945	Pharmaceutical compositions of linagliptin and process for preparation thereof In force Term ends Mar 31, 2035 · From the USPTO record	In force	Term ends Mar 31, 2035	From the USPTO record
US 10,632,043	Premix formulation for parenteral use and packaging thereof In force Term ends Nov 10, 2036 · From the USPTO record	In force	Term ends Nov 10, 2036	From the USPTO record
US 10,836,693	Process for the preparation of docosanol In force Term ends May 28, 2038 · From the USPTO record	In force	Term ends May 28, 2038	From the USPTO record
US 11,974,996	Naloxegol oxalate and solid dispersion thereof In force Term ends Jul 12, 2038 · From the USPTO record	In force	Term ends Jul 12, 2038	From the USPTO record
US 11,857,559	Pharmaceutical composition comprising Canagliflozin, process of preparation and use thereof In force Term ends Nov 26, 2038 · From the USPTO record	In force	Term ends Nov 26, 2038	From the USPTO record
US 11,273,156	Stable cariprazine formulations for oral use In force Term ends Apr 16, 2040 · From the USPTO record	In force	Term ends Apr 16, 2040	From the USPTO record
US 11,648,242	Pharmaceutical Composition Comprising Pimavanserin, Process of Preparation and Use Thereof In force Term ends Mar 16, 2041 · High confidence	In force	Term ends Mar 16, 2041	High confidence
US 11,969,413	Pharmaceutical compositions of deutetrabenazine and process for preparation thereof In force Term ends Oct 26, 2041 · From the USPTO record	In force	Term ends Oct 26, 2041	From the USPTO record
US 12,221,440	Process for the preparation of trametinib acetic acid solvate In force Term ends Apr 24, 2042 · From the USPTO record	In force	Term ends Apr 24, 2042	From the USPTO record
US 12,285,411	Pharmaceutical composition comprising eluxadoline, process of preparation and use thereof In force Term ends Nov 10, 2042 · From the USPTO record	In force	Term ends Nov 10, 2042	From the USPTO record

Also on record, not counted in the 10: 45 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

2 pending · 15 no status recorded

List them